Brief: SK Life Science Announces FDA Acceptance For Review Of New Drug Application For Cenobamate Oral Suspension
15/06/2026 16:06
BRIEF-SK Life Science Announces FDA Acceptance For Review Of New Drug Application For Cenobamate Oral Suspension June 15 (Reuters) - SK Biopharmaceuticals Co Ltd 326030.KS:
SK LIFE SCIENCE, INC. ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF NEW DRUG APPLICATION FOR CENOBAMATE ORAL SUSPENSION
Source text: ID:nPn9r4VDBa
Further company coverage: 326030.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SK Biopharmaceuticals Co
See all newsInsilico Medicine hits 3-week high on SK Biopharmaceuticals tie-up
Signs Joint Rd Partnership Agreement With Insilico Medicine
Brief: Insilico Medicine Cayman TopCo Says Co & SK Biopharmaceuticals Enter AI-Powered RD Collab Worth Up To $2.5 Bln
Brief: SK Life Science Announces FDA Acceptance For Review Of New Drug Application For Cenobamate Oral Suspension
Announces Pharmaceutical Supply Contract